Shenlin Huang Selected Research

1- (4- (6- amino- 5- (methoxyiminomethyl)pyrimidin- 4- yloxy)- 2- chlorophenyl)- 3- ethylurea

1/2009

A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shenlin Huang Research Topics

Disease

7	Neoplasms (Cancer) 01/2021 - 08/2007
1	Carcinoma (Carcinomatosis) 04/2016
1	Colorectal Neoplasms (Colorectal Cancer) 04/2016
1	Neoplasm Metastasis (Metastasis) 01/2009
1	Corneal Neovascularization 01/2009

Drug/Important Bio-Agent (IBA)

2	Ferritins (Ferritin)IBA 01/2021 - 12/2019
1	Peptides (Polypeptides)IBA 01/2021
1	Paclitaxel (Taxol)FDA LinkGeneric 12/2019
1	Antineoplastic Agents (Antineoplastics)IBA 12/2019
1	Pharmaceutical PreparationsIBA 12/2019
1	RAF709IBA 01/2017
1	benzamideIBA 01/2017
1	Phosphotransferases (Kinase)IBA 01/2017
1	PyransIBA 01/2017
1	MorpholinosIBA 01/2017
1	Fluorouracil (Carac)FDA LinkGeneric 04/2016
1	Long Noncoding RNAIBA 04/2016
1	Nerve Growth Factor (NGF)IBA 02/2012
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2009
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2009
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2009
1	1- (4- (6- amino- 5- (methoxyiminomethyl)pyrimidin- 4- yloxy)- 2- chlorophenyl)- 3- ethylureaIBA 01/2009
1	benzocycloheptapyridineIBA 08/2007

Therapy/Procedure

1	Therapeutics 12/2019
1	Lasers (Laser) 12/2019